Frontiers in Oncology · 2023 · 11 citations · 14 references
MedicineOncologyPharmacotherapyChemotherapyImmunotherapyTumor ProgressionCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ChemotherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationCetuximab TherapyCheckpoint Inhibitor CombinationsImmune Checkpoint Blockade CombinationsImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor TherapyMetastatic Squamous Cell CarcinomaPembrolizumab TherapyPlatinum Sensitivity
Background: Immune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall response rate (ORR) is limited to 10-20%, and subsequent chemotherapy is critical to maximizing the subjects' prognosis. Methods: We retrospectively reviewed 59 patients with R/M SCCHN treated with paclitaxel+cetuximab (PE)-based chemotherapy (PCE, paclitaxel+carboplatin+cetuximab; or PTX+Cmab, paclitaxel+cetuximab) following disease progression after either pembrolizumab or nivolumab monotherapy. Results: Of 59 patients, 15 were treated with pembrolizumab, with an ORR of 13.3%, and the remaining 44 with nivolumab, with an ORR of 11.4%. All patients in the pembrolizumab cohort had platinum-sensitive disease. Following ICI treatment, 19 patients were treated with PCE and the remaining 40 with PTX+Cmab. PE-based chemotherapy induced favorable and prompt tumor shrinkage even in cases where ICI was not effective, with a median change in the summed dimensions of target lesions of -43.4%, resulting in an ORR of 62.7%. Median time to response was 1.8 months. The patients in the pembrolizumab cohort appeared to have a numerically higher response rate than those receiving nivolumab (80.0% vs. 56.8%). For the 59 patients, progression-free survival and overall survival, calculated from the initiation of PE-based chemotherapy, were 4.6 months and 17.1 months, respectively. Grade ≥3 adverse events occurred in 40.7%, and no treatment-related death was observed. Conclusion: PE-based chemotherapy following ICI is encouraging for its robust antitumor efficacy in R/M SCCHN.
14
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text
Medicine, Oncology, Metastasis +5
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Jan B. Vermorken, Fernando Rivera, Éva Remenár et al. · New England Journal of Medicine · 2008 · 3.7K citations · Full text
Medicine, Oncology, Pharmacology +16
Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text
Kevin J. Harrington, Barbara Burtness, Richard Greil et al. · Journal of Clinical Oncology · 2022 · 490 citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Assuntina G. Sacco, Ruifeng Chen, Francis P. Worden et al. · The Lancet Oncology · 2021 · 258 citations · Full text